Kristen is the Founder and CEO of BIOAGE Labs, a biotechnology company that leverages AI for drug discovery and treatment for age-related diseases. Before beginning BIOAGE in 2015, Kristen spent over a decade in academia studying human longevity. In December of 2020, BIOAGE raised a $90M series C round of funding led by Andreessen Horowitz and previous podcast guest Elad Gil. Additional information about BIOAGE and its current job opportunities can be found at bioagelabs.com.
\n[0:10] - Kristen's lifelong interest in longevity science
\n[3:31] - Lessons from historical longevity breakthroughs
\n[10:26] - Early strategies and focus areas for BIOAGE
\n[16:38] - The need for increased government funding for aging
\n[18:58] - Translating human data into longevity solutions
\n[22:28] - Reviewing BIOAGE's initial drug discoveries and ongoing clinical trials
\n[27:51] - Picking up business fundamentals with a scientific background
\n[31:21] - The present and future of the longevity space
\n[38:44] - Kristen's philosophical perspective on extending human lifespans
\n[41:36] - The investment thesis for longevity technology
\n---
\n